Atypical depression in the 21st century: Diagnostic and treatment issues

Psychiatric Times

Volumn 28, Issue 1, 2011, Pages 42-46

  Cristancho, Mario A ^a   O'Reardon, John P ^a   Thase, Michael E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79951483410     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Gillespie RD. The clinical differentiation of types of depression. Guy Hosp Rep. 1929;79:306-344.
2. Kilon LG, Garside RF. Depression: a multivariate study of Sir Aubrey Lewis's data on melancholia. Aust N Z J Psychiatry. 1977;11:149-156. (Pubitemid 8191615)
3. Thase ME. Atypical depression: useful concept, but it's time to revise the DSM-W criteria. Neuropsychopharmacology. 2009;34:2633-2641.
4. Thase ME. Recognition and diagnosis of atypical depression. J Clin Psychiatry. 2007;68(suppl 8):11-16. (Pubitemid 47184566)
5. West ED, Dally PJ. Effect of iproniazid in depressive syndromes. Br Med J. 1959;1:1491-1494.
6. Robinson DS, Nies A, Ravaris CL, Lamborn KR. The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states. A controlled clinical trial. Arch Gen Psychiatry. 1973;29:407-413.
7. Quitkin F, Rifkin A, Klein DF. Monoamine oxidase inhibitors. A review of antidepressant effectiveness. Arch Gen Psychiatry. 1979;36:749-760. (Pubitemid 10102538)
8. Davidson JR, Miller RD, Turnbull CD, Sullivan JL Atypical depression. Arch Gen Psychiatry. 1982;39:527-534.
9. Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine versus Imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry. 1988;145:306-311. (Pubitemid 18078309)
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
11. Nierenberg AA, Alpert JE, Pava J, et al. Course and treatment of atypical depression. J Clin Psychiatry. 1998;59(suppl 18):5-9. (Pubitemid 28538507)
12. Quitkin FM. Depression with atypical features: diagnostic validity, prevalence, and treatment. Prim Care Companion J Clin Psychiatry. 2002;4:94-99.
13. McGrath PJ, Stewart JW, Harrison WM, et al. Predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol. 1992;12:197-202.
14. Kendler KS, Eaves U, Walters EE, et al. The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Arch Gen Psychiatry. 1996;53:391-399. (Pubitemid 26149227)
15. Sullivan PF, Kessler RC, Kendler KS. Latent class analysis of lifetime depressive symptoms in the national comorbidity survey. Am J Psychiatry. 1998;155:1398-1406. (Pubitemid 28471197)
16. Horwath E, Johnson J, Weissman MM, Hornig CD. The validity of major depression with atypical features based on a community study. J Affect Disord. 1992;26:117-125.
17. Levitan RD, Lesage A, Parikh SV, et al. Reversed neurovegetative symptoms of depression: a community study of Ontario. Am J Psychiatry. 1997;154:934-940. (Pubitemid 27274535)
18. Asnis GM, McGinn LK, Sanderson WC. Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry. 1995;152:31-36.
19. Robertson HA, Lam RW, Stewart JN, et al. Atypical depressive symptoms and clusters in unipolar and bipolar depression. Acta Psychiatr Scand. 1996;94:421-427. (Pubitemid 27028803)
20. Zisook S, Shuchter SR, Gallagher T, Sledge P. Atypical depression in an outpatient psychiatric population. Depression. 1993;1:268-274.
21. Angst J, Gamma A, Sellara R, et al. Toward validation of atypical depression in the community: results of the Zurich cohort study. J Affect Disord. 2002;72:125-138. (Pubitemid 35007357)
22. Novick JS, Stewart JW, Wisniewski SR, et al; STAR*D Investigators. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STARD'D. J Clin Psychiatry. 2005;66:1002-1011. (Pubitemid 41191792)
23. Benazzi F. Testing DSM-IV definition of atypical depression. Ann Clin Psychiatry. 2003;15:9-16. (Pubitemid 36723636)
24. Angst J, Gamma A, Benazzi F, et al. Atypical depressive syndromes in varying definitions. Eur Arch Psychiatry Clin Neurosci. 2006;256: 44-54. (Pubitemid 43288243)
25. Perugi G, Aklskal HS, Lattanzl L, et al.The high prevalence of "soft" bipolar (II) features in atypical depression. Compr Psychiatry. 1998; 39:63-71. (Pubitemid 28093926)
26. Stewart JW, McGrath PJ, Quitkin FM. Do age of onset and course of illness predict different treatment outcome among DSM IV depressive disorders with atypical features? Neuropsychopharmacology. 2002;26:237-245. (Pubitemid 34093086)
27. Alpert JE, Uebelacker LA, McLean NE, et al. Social phobia, avoidant personality disorder and atypical depression: co-occurrence and clinical implications. Psychol Med. 1997;27:627-633. (Pubitemid 27216188)
28. Posternak MA, Zimmerman M. Partial validation of the atypical features subtype of major depressive disorder. Arch Gen Psychiatry. 2002;59:70-76. (Pubitemid 34044409)
29. Thase ME, Carpenter L, Kupfer DJ, Frank E. Clinical significance of reversed vegetative subtypes of recurrent major depression. Psychopharmacol Bull. 1991;27:17-22.
30. Parker G, Roy K, Mittchel P, et al. Atypical depression: a reappraisal. Am J Psychiatry. 2002;159:1470-1479. (Pubitemid 35006725)
31. Henkel V, Mergl R, Coyne JC, et al. Depression with atypical features in a sample of primary care outpatients: prevalence, specific characteristics and consequences. J Affect Disord. 2004;83:237-242. (Pubitemid 39536201)
32. Quitkin FM, McGrath PJ, Stewart JW, et al. Phenelzine and Imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. Arch Gen Psychiatry. 1989;46:787-793. (Pubitemid 19233227)
33. McGrath PJ, Stewart JW, Harrison W, et al. Phenelzine treatment of melancholia. J Clin Psychiatry. 1986;47:420-422. (Pubitemid 16045147)
34. McGrath PJ, Quitkin FM, Harrison W, Stewart JW. Treatment of melancholia with tranylcypromine. Am J Psychiatry. 1984;141:288-289. (Pubitemid 14180982)
35. Quitkin FM, McGrath P, Liebowitz MR, et al. Monoamine oxidase inhibitors in bipolar endogenous depressives. J Clin Psychopharmacol. 1981;1:70-74. (Pubitemid 12246898)
36. Himmelhoch JM, Fuchs CZ, Symons BJ. A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis. 1982;170:628-634. (Pubitemid 12036008)
37. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991;148:910-916.
38. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: a double-blind, crossover study of tranylcypromine in anergic bipolar depression. Am J. Psychiatry. 1992;149:195-198.
39. Anisman H, Ravindran AV, Griffiths J, Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry. 1999;4:182-188. (Pubitemid 29163982)
40. Stewart JW, Quitkin FM, McGrath PJ, Klein DF. Defining the boundaries of atypical depression: evidence from the HPA axis supports course of illness distinctions. J Affect Disord. 2005;86:161-167. (Pubitemid 40780028)
41. Fotiou F, Fountoulakis KN, lacovides A, Kaprinis G. Pattern-reversed visual evoked potentials in subtypes of major depression. Psychiatry Res. 2003;118:259-271. (Pubitemid 36776654)
42. Bruder GE, Quitkin FM, Stewart JW, et al. Cerebral laterality and depression: differences in perceptual asymmetry among diagnostic subtypes. J Abnorm Psychol. 1989;98:177-186. (Pubitemid 19134405)
43. Bruder GE, Stewart JW, McGrath PJ, et al. Atypical depression: enhanced right hemispheric dominance for perceiving emotional chimeric faces. J Abnorm Psychol. 2002;111:446-454. (Pubitemid 34791145)
44. Stewart JW, McGrath PJ, Quitkin FM, Klein DF. DSM-IV depression with atypical features: is it valid? Neuropsychopharmacology. 2009; 34:2625-2632.
45. Stewart JW, Bruder GE, McGrath PJ, Quitkin FM. Do age of onset and course of illness define biologically distinct groups within atypical depression? J Abnorm Psychol. 2003;112:253-262. (Pubitemid 36583180)
46. Fountoulakis KN, lacovides A, Gerasimou G, et al. The relationship of regional cerebral blood flow with subtypes of major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:537-546. (Pubitemid 38490767)
47. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl. 1993;21:30-34. (Pubitemid 23271368)
48. Sargent W. Drugs in the treatment of depression. Br Med J. 1961:225-227.
49. Dally PJ, Rohde P. Comparison of antidepressant drugs in depressive illness. Lancet 1961 ;1:18-20.
50. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res. 1986;17:87-95. (Pubitemid 16175043)
51. Paykel ES, Rowan PR, Parker RR, Bhat AV. Response to phenelzine and amitriptyline in subtypes of outpatient depression. Arch Gen Psychiatry. 1982;39:1041-1049. (Pubitemid 12020987)
52. Henkel V, Mergl R, Allgaier A, et al. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res. 2006; 141:89-101. (Pubitemid 43011354)
53. Thase ME, Trivedi MH, Rush AJ. MAOIs In the contemporary treatment of depression. Neuropsychopharmacology. 1995;12:185-219.
54. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45:129-137. (Pubitemid 18052843)
55. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to Imipramine and phenelzine. A replication. Arch Gen Psychiatry. 1990;47:935-941. (Pubitemid 20348481)
56. Quitkin FM, Harrison W, Stewart JW, et al. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Arch Gen Psychiatry. 1991 ; 48:319-323.
57. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of Imipramine and phenelzine for outpatients with treatmentrefractory depression. Am J Psychiatry. 1993;150:118-123. (Pubitemid 23059175)
58. Pande AC, Birkett M, Fechner-Bates S, et al. Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry. 1996;40:1017-1020. (Pubitemid 26391679)
59. Lonnqvist J, Sihvo S, Syvälahti E, Kiviruusu O. Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord. 1994;32:169-177. (Pubitemid 24341681)
60. Segaard J, Lane R, Latimer P, et al. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol. 1999;13:406-414. (Pubitemid 30055186)
61. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999; 20:226-247. (Pubitemid 29067402)
62. McGrath PJ, Stewart JW, Janal MN, et al. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry. 2000;157:344-350. (Pubitemid 30145918)
63. Quitkin FM, Liebowitz MR, Stewart JW, et al. L-deprenyl in atypical depressives. Arch Gen Psychiatry. 1984;41:777-781. (Pubitemid 14092256)
64. McGrath PJ, Stewart JW, Harrison W, et al. A placebo controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull. 1989; 25:63-67. (Pubitemid 19179162)
65. Jarrett RB, Schaffer M, Mclntire D, et al. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56:431-437. (Pubitemid 29215432)
66. Sotsky SM, Glass DR, Shea MT, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry. 1991;148:997-1008.
67. Stewart JW, Garfinkel R, Nunes EV, et al. Atypical features and treatment response in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Clin Psychopharmacol. 1998;18:429-434. (Pubitemid 28555324)
68. Sargent W. Some newer drugs in the treatment of depression and their relation to other somatic treatments. Psychosomatics. 1960;1: 14-19.
69. Husain MM, McClintock SM, Rush AJ, et al. The efficacy of acute electroconvulsive therapy in atypical depression. J Clin Psychiatry. 2008;69:406-411. (Pubitemid 351549393)